Background {#sec1}
==========

Glioblastoma, also known as glioblastoma multiforme (GBM), is the most common primary brain tumor, with aggressive clinical manifestation \[[@B1]\]. The incidence rate of central nervous system tumors was reported to be 6.7 per 100,000 persons in 2000 \[[@B2]\]. Some researchers have demonstrated an increase in the incidence of brain tumors, which was partly result of the developments in diagnosis and changes in the classification system \[[@B3]\]. Despite radiotherapy plus temozolomide (TMZ) provided 2- and 5-year survival rates of 27 and 10%, median survival in GBM is generally less than 1 year, and even the patients with favorable situations, the survival month is still less than 2 years \[[@B4]\]. Except for Turcot's syndrome and Li--Fraumeni syndrome, most GBM patients originate in a sporadic fashion without any known predisposing factors \[[@B8]\]. Therefore, little is known about the risk factors for brain tumors \[[@B9]\]. A better understanding of the distribution of GBM may provide indications of etiologic factors and contribute to the search for improved therapies.

Gender-related discrepancies in the incidence and survival of hepatocellular carcinoma \[[@B10]\], colorectal \[[@B11]\], and gastric cancers \[[@B12]\] have previously been reported. Above results support the protective role of estrogen in these malignancies. However, the protective role in GBM has not been investigated in a large population. To further clarify the issue of gender on GBM prognosis, Surveillance, Epidemiology, and End Results (SEER) population-based data were analyzed in our study.

Methods {#sec2}
=======

Patients {#sec2-1}
--------

The current SEER database consists of 17 population-based cancer registries representing approximately 26% of the U.S. population. The SEER Cancer Statistics Review (<http://seer.cancer.gov/data/citation.html>)---a report on the most recent cancer incidence, mortality, survival, prevalence, and lifetime risk statistics---is published annually by the Data Analysis and Interpretation Branch of the National Cancer Institute (Rockville, MD, U.S.A.). SEER data contain no identifiers and are publicly available for studies of cancer-based epidemiology and survival analysis. The National Cancer Institute's SEER\*Stat software, version 8.1.5 (Surveillance Research Program; [www.seer.cancer.gov/seerstat](http://www.seer.cancer.gov/seerstat)) was used to identify patients whose pathological diagnosis as glioblastoma based on International Classification of Diseases for Oncology (ICD-O) topography codes (C71.0--C71.9) between 2000 and 2008. The definition of anatomical primary site of brain tumors was restricted to the following: C71.0-Cerebrum, C71.1-Frontal lobe, C71.2-Temporal lobe, C71.3-Parietal lobe, C71.4-Occipital lobe, C71.5-Ventricle, C71.6-Cerebellum, C71.7-Brain stem, C71.8-Overlapping lesion of brain, C71.9-Brain, and brain sites not otherwise specified (NOS). Morphology codes for glioblastoma were expanded to include the following histologies: 9440, 9441 and 9442 (i.e. glioblastoma, NOS, Giant cell glioblastoma, and Gliosarcoma). Only patients who underwent surgical treatment and who were between 18 and 70 years old at the time of diagnosis were included. Patients were excluded if they had incomplete staging, distant metastasis, or lacked an evaluation of histological type or follow-up. Age, sex, race, histological type, stage, tumor grade and size, and cancer-specific survival (CSS) were assessed. Adjuvant chemotherapy was not evaluated, since the SEER registry does not have this information. Tumor-node-metastasis classification was restaged according to criteria described in the American Joint Committee on Cancer Staging Manual (7th edition, 2010). The primary endpoint of the present study was CSS, which was calculated from the date of diagnosis to the date of cancer-related death. Deaths attributable to cancer were treated as events and deaths from other causes were treated as censored observations.

Ethics statement {#sec2-2}
----------------

The present study was based on public data from the SEER database, and permission was obtained to access the files (reference no. 12578-Nov2013). The analysis did not involve interaction with human subjects or use personal identifying information. The study did not require informed consent and was approved by the Review Board of Nanjing Medical University (Nanjing, China). Patient records/information was anonymized and de-identified prior to analysis, and the methods were carried out in accordance with the approved guidelines.

Statistical analysis {#sec2-3}
--------------------

The association between gender (male or female) and clinicopathological parameters was analyzed by the χ^2^ test. Continuous variables were analyzed using the Student's *t* test. Survival curves were generated based on Kaplan--Meier estimates, and differences between the curves were analyzed by the log-rank test. Multivariate Cox regression models were generated with hazard ratio (HR) and 95% confidence interval (CI) to analyze risk factors for survival. Statistical analyses were performed using SPSS version 17 for Windows (SPSS Inc., Chicago, IL, U.S.A.). Results were considered statistically significant for a two-tailed *P* value \< 0.05.

Availability of data and materials {#sec2-4}
----------------------------------

The datasets generated and/or analyzed during the present study are available in the SEER dataset repository. <https://seer.cancer.gov/>.

Results {#sec3}
=======

Patient characteristics {#sec3-1}
-----------------------

We identified 6586 eligible patients with GBM in the SEER database during the 8-year study period (between 2000 and 2008). A total of 4049 (61.5%) were men, and 2537 (38.5%) were women. The median follow-up period was 17 months. The median follow-up period was 17 months in the male group and 19 months in the female group. Patient demographics and pathologic features are summarized in [Table 1](#T1){ref-type="table"}.

###### Characteristics of patients from SEER Database by gender

                                               Number of patients (%)                              
  -------------------------------------------- ------------------------ ------------- ------------ ------------
  Media follow up (mo)                         17(5--20)                17(5--19)     19(5--22)    
  (IQR)                                                                                            
  Years of diagnosis                                                                               0.533
    2000--2004                                 3469(52.7)               2145(53.0)    1324(52.2)   
    2005--2008                                 3117(47.3)               1904(47.0)    1213(47.8)   
  Age                                                                                              0.296
    \<40                                       581(8.8)                 358(8.8)      223(8.8)     
    41--60                                     3635(55.2)               2263 (55.9)   1372(54.1)   
    \>60                                       2370(36.0)               1428(35.3)    942(37.1)    
  Race                                                                                             *P*\<0.001
    Caucasian                                  5425(82.4)               3361(83.0)    878(34.6)    
    African American                           914(13.9)                384(9.5)      312(12.3)    
    Others[\*](#T1TFN1){ref-type="table-fn"}   2282(34.6)               1712(42.3)    209(8.2)     
  Primary site                                                                                     0.870
    Cerebrum                                   235(3.6)                 144(3.6)      91(3.6)      
    Frontal lobe                               1663(25.3)               1028(25.4)    635(25.0)    
    Temporal lobe                              1556(23.6)               957(23.6)     599(23.6)    
    Parietal lobe                              1097(16.7)               661(16.3)     436(17.2)    
    Occipital lobe                             274(4.2)                 158(3.9)      116(4.6)     
    Ventricle, NOS                             27(0.4)                  15(0.4)       12(0.5)      
    Cerebellum, NOS                            36(0.5)                  22(0.5)       14(0.6)      
    Brain stem                                 28(0.5)                  19(0.5)       9(0.4)       
    Overlapping lesion of brain                1158(17.6)               719(17.8)     439(17.3)    
    Brain, NOS                                 512(7.8)                 326(8.1)      186(7.3)     
  Pathological grading                                                                             0.144
    High/Moderate                              25(0.4)                  20 (0.5)      5 (0.2)      
    Poor/UD                                    2655(40.3)               1640(40.5)    1015(40.0)   
    Unknown                                    3906(59.3)               2389(59.0)    1517(59.8)   
  Stage                                                                                            0.127
    Localized                                  5067(76.9)               3152 (77.8)   1915(75.5)   
    Regional                                   1172(17.8)               697(17.2)     475 (18.7)   
    Distant                                    70(1.1)                  38(0.9)       32(1.3)      
    Unstaged                                   277(4.2)                 162(4.0)      115(4.5)     
  Tumor size                                                                                       0.015
    \<3 cm                                     797 (12.1)               463 (11.4)    334 (13.2)   
    3--5 cm                                    2498(37.9)               1511(37.3)    987 (38.9)   
    \>5 cm                                     1666(25.3)               1071(26.5)    595(23.5)    
    Not stated                                 1625(24.7)               1004(24.8)    621(24.5)    

Abbreviation: NOS, not otherwise specified.

including other (American Indian/AK Native, Asian/Pacific Islander) and unknowns.

Clinicopathological differences between the groups {#sec3-2}
--------------------------------------------------

As illustrated in [Table 1](#T1){ref-type="table"}, there were significant differences observed between the two groups, including race (more frequent in Caucasian, 82.4%; *P*\<0.001) and tumor size (more 3--5 cm, 37.9%; *P*=0.015). Whereas, no differences were observed in years of diagnosis, age, primary site, pathological grading, and stage between the two groups.

Impact of gender on survival outcomes {#sec3-3}
-------------------------------------

The univariate log-rank test showed that the 1-, 3- and 5-year CSS were 45.9%, 11.4% and 6.8% in male group, 47.9%, 14.3% and 8.3% in female group (*P*=0.002) ([Figure 1](#F1){ref-type="fig"}). Moreover, an early year of diagnosis (2000--2004), age more than 60 years, African American race, brain stem tumor, poor/undifferentiated tumor grade (*P*=0.014), higher stage, and larger tumor size (*P*\<0.001) were regarded as significant risk factors by univariate analysis ([Table 2](#T2){ref-type="table"}). Multivariate analysis with Cox regression was performed, and the following seven factors were found to be independent prognostic factors ([Table 3](#T3){ref-type="table"}), including year of diagnosis (2005--2008: HR, 0.783; 95% CI, 0.743--0.826), gender (female: HR, 0.906; 95% CI, 0.859--0.954), age (41--60 years: HR, 2.036; 95% CI, 1.840--2.254; \>60 years: HR, 3.033; 95% CI, 2.729--3.371), race (African American: HR, 1.025; 95% CI, 0.908--1.158), primary site (frontal lobe: HR, 0.996; 95% CI, 0.861--1.151; temporal lobe: HR, 1.018; 95% CI, 0.880--1.178; parietal lobe: HR, 0.953; 95% CI, 0.821--1.107; occipital lobe: HR, 1.025; 95% CI, 0.853--1.232; ventricle, NOS: HR, 1.268; 95% CI, 0.848--1.898; cerebellum, NOS: HR, 1.044; 95% CI, 0.719--1.516; brain stem: HR, 1.518; 95% CI, 1.023--2.254; overlapping lesion of brain: HR, 0.983; 95% CI, 0.847--1.141; brain, NOS: HR, 0.787; 95% CI, 0.667--0.929); pathological grading (poor/undifferentiated: HR, 1.418; 95% CI, 0.912--2.205), stage (regional: HR, 1.568; 95% CI, 1.465--1.678; distant: HR, 1.580; 95% CI, 1.238--2.017), tumor size (3--5 cm: HR, 1.029; 95% CI, 0.946--1.119; \>5 cm: HR 1.145; 95% CI, 1.046--1.253).

![Kaplan--Meier estimates of glioblastoma cancer caused-specific survival in different gender groups\
(**A**) The overall group; male versus female: χ2 = 9.616, *P*=0.002. (**B**) The localized stage group; male versus female: χ2 = 12.959, *P*\<0.001.](bsr-38-bsr20180752-g1){#F1}

###### Univariate survival analyses of GBM patients according to various clinicopathological variables

  Variable                                     *N*    1-year CSS (%)   3-year CSS (%)   5-year CSS (%)   Log rank χ2 test   *P*
  -------------------------------------------- ------ ---------------- ---------------- ---------------- ------------------ ------------
  Years of diagnosis                                                                                     61.795             *P*\<0.001
    2000--2004                                 3469   41.7%            10.2%            6.5%                                
    2005--2008                                 3117   52.1%            15.0%            8.3%                                
  Gender                                                                                                 9.616              0.002
    Male                                       4049   45.9%            11.4%            6.8%                                
    Female                                     2537   47.9%            14.3%            8.3%                                
  Age                                                                                                    477.901            *P*\<0.001
    \<40                                       581    74.3%            35.0%            26.1%                               
    41--60                                     3635   50.5%            12.3%            6.9%                                
    \>60                                       2370   33.7%            7.2%             3.5%                                
  Race                                                                                                   29.078             *P*\<0.001
    Caucasian                                  5425   46.2%            11.6%            7.0%                                
    African American                           914    45.8%            16.8%            9.9%                                
    Others[\*](#T2TFN1){ref-type="table-fn"}   2282   55.8%            24.3%            13.9%                               
  Primary site                                                                                           51.553             *P*\<0.001
    Cerebrum                                   235    49.5%            11.2%            6.2%                                
    Frontal lobe                               1663   47.6%            11.1%            7.1%                                
    Temporal lobe                              1556   44.2%            10.8             5.5                                 
    Parietal lobe                              1097   45.3%            14.3%            7.9%                                
    Occipital lobe                             274    42.3%            11.8%            4.7%                                
    Ventricle, NOS                             27     29.6%            3.7%             NI                                  
    Cerebellum, NOS                            36     53.5%            11.9             5.9                                 
    Brain stem                                 28     28.6%            3.6%             NI                                  
    Overlapping lesion of brain                1158   46.3%            13.3%            7.9%                                
    Brain, NOS                                 512    56.9%            18.3%            13.9%                               
  Pathological grading                                                                                   8.529              0.014
    High/Moderate                              25     68.0%            32.0%            22.4%                               
    Poor/UD                                    2655   46.8%            12.0%            7.2%                                
    Unknown                                    3906   46.4%            12.7%            7.4%                                
  Stage                                                                                                  159.412            *P*\<0.001
    Localized                                  5067   50.5%            13.7%            8.1%                                
    Regional                                   1172   32.1%            7.3%             4.8                                 
    Distant                                    70     30.3%            4.5%             NI                                  
    Unstaged                                   277    41.4%            13.7%            7.9                                 
  Tumor size                                                                                             29.108             *P*\<0.001
    \<3 cm                                     797    53.2             14.0             7.5                                 
    3--5 cm                                    2498   49.7             13.1             7.6                                 
    \>5 cm                                     1666   43.4             12.4             7.5                                 
    Not stated                                 1625   42.0             10.8             7.1                                 

Abbreviation: NI, not included.

including other (American Indian/AK Native, Asian/Pacific Islander) and unknowns.

###### Multivariate Cox model analyses of prognostic factors of GBM

  Variable                                     Hazard ratio   95%CI          *P*
  -------------------------------------------- -------------- -------------- ------------
  Years of diagnosis                                                         *P*\<0.001
    2000--2004                                 1              Reference      
    2005--2008                                 0.783          0.743--0.826   
  Gender                                                                     
    Male                                       1              Reference      *P*\<0.001
    Female                                     0.906          0.859--0.954   
  Age                                                                        *P*\<0.001
    \<40                                       1              Reference      
    41--60                                     2.036          1.840--2.254   
    \>60                                       3.033          2.729--3.371   
  Race                                                                       *P*\<0.001
    Caucasian                                  1              Reference      
    African American                           1.025          0.908--1.158   
    Others[\*](#T3TFN1){ref-type="table-fn"}   0.750          0.663--0.848   
  Primary site                                                               *P*\<0.001
    Cerebrum                                   1              Reference      
    Frontal lobe                               0.996          0.861--1.151   
    Temporal lobe                              1.018          0.880--1.178   
    Parietal lobe                              0.953          0.821--1.107   
    Occipital lobe                             1.025          0.853--1.232   
    Ventricle, NOS                             1.268          0.848--1.898   
    Cerebellum, NOS                            1.044          0.719--1.516   
    Brain stem                                 1.518          1.023--2.254   
    Overlapping lesion of brain                0.983          0.847--1.141   
    Brain, NOS                                 0.787          0.667--0.929   
  Pathological grading                                                       0.178
    High/Moderate                              1              Reference      
    Poor/UD                                    1.418          0.912--2.205   
    Unknown                                    1.454          0.935--2.259   
  Stage                                                                      *P*\<0.001
    Localized                                  1              Reference      
    Regional                                   1.568          1.465--1.678   
    Distant                                    1.580          1.238--2.017   
    Unstaged                                   0.988          0.865--1.129   
  Tumor size                                                                 *P*\<0.001
    \<3 cm                                     1              Reference      
    3--5 cm                                    1.029          0.946--1.119   
    \>5 cm                                     1.145          1.046--1.253   
    Not stated                                 1.158          1.056--1.269   

including other (American Indian/AK Native, Asian/Pacific Islander) and unknowns.

Stratified analysis of gender effect on CSS rates {#sec3-4}
-------------------------------------------------

We then further analyzed the effect of gender on CSS rates in each stage ([Figure 1](#F1){ref-type="fig"}). The univariate analysis of gender on CSS showed that female had increased 1-, 3-, and 5-year CSS in localized stage (*P*\<0.001), but not in regional (*P*=0.619) and distant stage (*P*=0.259). And gender was validated as an independent predictor of survival in multivariate Cox regression in the localized stages (*P*\<0.001) ([Figure 1](#F1){ref-type="fig"}) ([Table 4](#T4){ref-type="table"}). Furthermore, we made further stratified analysis of survival rates and hazard by age ([Figure 2](#F2){ref-type="fig"}). Male always had the lowest CSS rate in 41--60 years and \>60 years group, which were consistent with above results ([Table 5](#T5){ref-type="table"}).

###### Univariate and multivariate analyses for evaluating gender influencing CSS in GBM based on different cancer stage

              Univariate analysis                 Multivariate analysis                                      
  ----------- --------------------- ------ ------ ----------------------- ------------ --------------------- ------------
  Localized                                                                                                  
  Gender                                          12.959                  *P*\<0.001                         *P*\<0.001
    Male      49.3                  12.4   7.2                                         Reference             
    Female    52.4                  15.8   9.3                                         0.898(0.845--0.954)   
  Regional                                                                                                   
  Gender                                          0.247                   0.619                              
    Male      31.7                  6.3    5.1%                                                              
    Female    32.7                  8.6    4.4%                                                              
  Distant                                                                                                    
  Gender                                          1.273                   0.259                              
    Male      39.4                  5.6    NI                                                                
    Female    16.4                  3.3    NI                                                                

![Subgroup analysis for evaluating the effect of gender for glioblastoma patients according to different age\
(**A**) 41--60 years: χ2 = 8.389, *P*=0.004; (**B**) \>60 years: χ2 = 6.233, *P*=0.013.](bsr-38-bsr20180752-g2){#F2}

###### Univariate and multivariate analyses for evaluating gender influencing CSS in GBM based on different age

             Univariate analysis                  Multivariate analysis                                 
  ---------- --------------------- ------ ------- ----------------------- ------- --------------------- ------------
  \<40                                                                                                  
  Gender                                          0.072                   0.788                         NI
    Male     75.9                  34.6   26.1%                                                         
    Female   71.9                  35.6   24.9%                                                         
  41--60                                                                                                
  Gender                                          8.389                   0.004                         0.003
    Male     49.3                  11.0   6.1%                                    Reference             
    Female   52.5                  14.4   7.8%                                    0.899(0.837--0.965)   *P*\<0.001
  \>60                                                                                                  
  Gender                                          6.233                   0.013                         0.029
    Male     32.6                  6.0    2.4%                                    Reference             
    Female   35.2                  8.9    4.9%                                    0.908(0.832--0.990)   

NI: not included in multivariate survival analysis.

*P* values were adjusted for years of diagnosis, age, race, pathological grading, stage and tumor size as covariates between the two groups.

Discussion {#sec4}
==========

GBM accounts for 17% of intracranial tumors and be considered as the most common brain tumor in adults \[[@B13]\]. Despite surgical resection followed by adjuvant radiotherapy and chemotherapy has been applied, prognosis remains poor and long-term survival is rare \[[@B14]\]. Thus, further understanding and improvements in GBM prognosis may affect the choice of salvage therapy and follow-up strategies.

The higher percentage of GBM in men compared with women has been reported in some literature, with a mean male/female ratio ranging from 1.0 to 1.9 \[[@B15]\]. However, to the best of our knowledge, there is limited information regarding the impact of sex on survival in patients with GBM. Our study revealed a correlation between female sex and improved CSS and OS in patients with GBM. This survival discrepancy still existed after stratified analysis. Interestingly, female patients have an equivalent percentage in poor/undifferentiation grade (40.0% versus 40.5%) and more than 3 cm tumor size (63.8% versus 62.4%) when compared with male patients. In addition, even after adjusting confounding factors, gender remained to serve as an independent prognostic predictor.

Sex disparities in cancer mortality arise from the sex differences have been analyzed widely. However, the evidence regarding the influence of reproductive factors and hormones on GBM has not been well verified. Epidemiological studies provided very limited evidence regarding the impact of sex on survival in patients with GBM \[[@B18]\]. Some studies have reported that female have longer survival than male \[[@B22],[@B23]\]. Barone et al. \[[@B24]\] demonstrated that estrogen increased survival in an orthotopic model of glioblastoma, and estradiol-based study may be beneficial in treating GBM. Li et al. \[[@B25]\]observed high frequency of estrogen receptor methylation GBMs, indicating that estrogen protect patients from GBM. Moreover, Yu et al. \[[@B26]\] found that androgen receptor signaling could promote tumorigenesis of GBM in adult men by inhibiting TGF-β (transforming growth factor β) receptor signaling. The findings of our study suggest that estrogen may protect against GBM genesis and promote a more favorable biology once GBM develops.

Univariate analysis showed that female had a better 1-, 3-, and 5-year CSS compared with male patients, but this failed to reach statistical significance in multivariable Cox regression models of regional and distant stages. A total of 4049 male GBM patients and 2537 females were included in our study, the largest sample size up to now. Due to the protective role of estrogen in the female groups, these patients exhibited better survival. The survival disadvantage in women aged more than 60 years may reflect the lasting effect of estrogen on the biology of GBM. In addition to the impact of sex on survival, we explored potential interactions between sex and age. Male patients were at an increased risk of cancer mortality in contrast with female patients with different age subgroups after adjusted for confounding factors. When comparing with male patients, female patients always had the worse CSS in regional and distant subgroups.

Although the present study is based on a large population, there are still limitations. First, its retrospective nature may affect the analysis. Second, several important pieces of information regarding GBM predisposing factors were not included in the SEER database. Moreover, current classification of tumors of the CNS does not include the term glioblastoma multiforme, thus we cannot adjust the nomenclature according to the newest criteria. Besides, information on menopausal status or use of hormone therapy was not included in the SEER database, thus limit our ability to reach definitive conclusions in this regard. Despite these limitations, our large population-based study may render our conclusions more convincing.

Conclusions {#sec5}
===========

The results of the present study demonstrate that sex influences survival among patients with GBM. Compared with male patients, female patients with GBM have a higher CSS after surgery. Future studies are warranted to validate these confounding factors and present unique opportunities for novel therapeutics.
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